Fatty Liver Disease

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 12 42 15
Fatty Liver 73 54 6 44 70
Fatty Liver, Alcoholic 44 70
Alcoholic Fatty Liver 12 32
Fatty Change of Liver 12
Fatty Liver Alcoholic 54
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 70


External Ids:

Disease Ontology 12 DOID:9452
ICD9CM 34 571.0
SNOMED-CT 67 371330000 50325005
ICD10 32 K70.0 K76.0
UMLS 70 C0015695 C0015696 C2711227

Summaries for Fatty Liver Disease

MedlinePlus : 42 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who is at risk for fatty liver disease? The cause of nonalcoholic fatty liver disease (NAFLD) is unknown. Researchers do know that it is more common in people who Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25 percent of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How is fatty liver disease diagnosed? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, is related to non-alcoholic steatohepatitis and liver disease. An important gene associated with Fatty Liver Disease is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are Metabolism and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Angiotensin II and Losartan have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and ovary, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia : 73 Fatty liver disease (FLD), also known as hepatic steatosis, is a condition where excess fat builds up in... more...

Related Diseases for Fatty Liver Disease

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 708)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic steatohepatitis 33.2 TNF PPARA PNPLA3 MTTP LEPR INS
2 liver disease 32.9 TNF SREBF1 SLC17A5 PPARA PNPLA3 MTTP
3 fatty liver disease, nonalcoholic 1 32.9 YARS1 PRMT7 PNPLA3
4 alcohol use disorder 32.5 SLC17A5 GPT GGT1 CYP2E1
5 hyperlipidemia, familial combined, 3 32.4 PPARA LEPR INS ADIPOQ
6 non-alcoholic fatty liver disease 32.3 YARS1 TNF SREBF1 PRMT7 PPARA PNPLA3
7 lipid metabolism disorder 32.2 SREBF1 PPARA MTTP LEP INSR INS
8 atherosclerosis susceptibility 32.1 TNF PPARA LEP INS ADIPOQ
9 viral hepatitis 32.0 TNF SLC17A5 PNPLA3 INS GPT GGT1
10 hyperuricemia 31.9 LEP INS GPT GGT1
11 sleep apnea 31.9 TNF LEPR LEP INS GPT ADIPOQ
12 polycystic ovary syndrome 31.8 LEP INSR INS ADIPOQ
13 hypothyroidism 31.8 TNF LEP INS GPT ADIPOQ
14 visceral steatosis, congenital 31.8 YARS1 PRMT7
15 coronary heart disease 1 31.8 MTTP INS ADIPOQ
16 hyperinsulinism 31.8 SREBF1 PPARA LEPR LEP INSR INS
17 hepatitis b 31.8 TNF SLC17A5 GPT GGT1
18 leptin deficiency or dysfunction 31.7 TNF SREBF1 PPARA LEPR LEP INS
19 chronic kidney disease 31.7 TNF LEPR LEP INS FABP1 ADIPOQ
20 arteries, anomalies of 31.7 TNF LEP INS ADIPOQ
21 glucose intolerance 31.7 TNF PPARA LEPR LEP INSR INS
22 portal hypertension 31.7 TNF PNPLA3 INS GPT
23 autoimmune hepatitis 31.7 TNF SLC17A5 GPT GGT1
24 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.5 LEP INS ADIPOQ
25 proteasome-associated autoinflammatory syndrome 1 31.4 TNF PPARA INS ADIPOQ
26 hyperandrogenism 31.4 INSR INS ADIPOQ
27 overnutrition 31.4 TNF SREBF1 PPARA LEPR LEP INS
28 alcoholic hepatitis 31.4 TNF SLC17A5 PNPLA3 GPT GGT1 CYP2E1
29 liver cirrhosis 31.3 TNF SLC17A5 PNPLA3 MALAT1 LEPR LEP
30 end stage renal disease 31.3 TNF LEP INS ADIPOQ
31 gestational diabetes 31.3 TNF LEPR LEP INSR INS ADIPOQ
32 hyperglycemia 31.3 MALAT1 LEP INSR INS ADIPOQ
33 cholelithiasis 31.3 LEP INS GPT
34 cholangitis 31.3 TNF GPT GGT1
35 apnea, obstructive sleep 31.2 TNF LEP INS GPT ADIPOQ
36 choline deficiency disease 31.2 SREBF1 PPARA GPT
37 arteriosclerosis 31.2 PPARA INS GPT ADIPOQ
38 wilson disease 31.2 TNF SLC17A5 PNPLA3 GPT
39 sleep disorder 31.2 TNF LEP INS ADIPOQ
40 hepatic encephalopathy 31.2 TNF SLC17A5 GPT
41 kwashiorkor 31.2 SLC17A5 INS GPT
42 alcohol dependence 31.2 TNF SLC17A5 LEP GGT1 CYP2E1
43 type 1 diabetes mellitus 31.1 TNF LEPR LEP INSR INS ADIPOQ
44 type 2 diabetes mellitus 31.1 TNF SREBF1 SLC17A5 PRMT7 PPARA PNPLA3
45 sclerosing cholangitis 31.1 TNF GPT GGT1
46 hypothalamic obesity 31.0 LEPR LEP INS
47 cerebrovascular disease 31.0 TNF LEP INS ADIPOQ
48 hypertension, essential 31.0 TNF SREBF1 PPARA LEPR LEP INSR
49 insulin-like growth factor i 31.0 LEP INSR INS
50 bilirubin metabolic disorder 31.0 TNF SLC17A5 INS GPT GGT1 CYP2E1

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):

Alcohol Use Disorder Alcoholic Hepatitis
Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:

Diseases related to Fatty Liver Disease

Symptoms & Phenotypes for Fatty Liver Disease

MGI Mouse Phenotypes related to Fatty Liver Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ADIPOQ ADIPOR2 CYP2E1 FABP1 GGT1 INS
2 growth/size/body region MP:0005378 10.24 ADIPOQ ADIPOR2 CYP2E1 GGT1 INS INSR
3 behavior/neurological MP:0005386 10.23 ADIPOQ ADIPOR2 CYP2E1 FABP1 GGT1 INS
4 adipose tissue MP:0005375 10.22 ADIPOQ ADIPOR2 INS INSR LEP LEPR
5 cellular MP:0005384 10.17 ADIPOQ ADIPOR2 GGT1 INS INSR LEP
6 liver/biliary system MP:0005370 10.13 ADIPOQ ADIPOR2 CYP2E1 FABP1 INS INSR
7 endocrine/exocrine gland MP:0005379 10.06 ADIPOQ ADIPOR2 GGT1 INS INSR LEP
8 mortality/aging MP:0010768 10 ADIPOQ CYP2E1 GGT1 INS INSR LEP
9 muscle MP:0005369 9.56 ADIPOQ INS INSR LEP LEPR PPARA
10 skeleton MP:0005390 9.32 ADIPOQ ADIPOR2 CYP2E1 GGT1 GPT INS

Drugs & Therapeutics for Fatty Liver Disease

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Losartan Approved Phase 4 114798-26-4 3961
Atorvastatin Approved Phase 4 134523-00-5 60823
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Glimepiride Approved Phase 4 93479-97-1 3476
Simvastatin Approved Phase 4 79902-63-9 54454
Amlodipine Approved Phase 4 88150-42-9 2162
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
Liraglutide Approved Phase 4 204656-20-2 44147092
Ezetimibe Approved Phase 4 163222-33-1 150311
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
Gliclazide Approved Phase 4 21187-98-4 3475
Insulin aspart Approved Phase 4 116094-23-6 16132418
Insulin detemir Approved Phase 4 169148-63-4 5311023
Phentermine Approved, Illicit Phase 4 122-09-8 4771
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
Empagliflozin Approved Phase 4 864070-44-0
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Alogliptin Approved Phase 4 850649-61-5 11450633
Polyestradiol phosphate Approved Phase 4 28014-46-2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
Methyltestosterone Approved Phase 4 58-18-4 6010
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
Testosterone Approved, Investigational Phase 4 58-22-0 6013
Testosterone enanthate Approved Phase 4 315-37-7 9416
Dulaglutide Approved, Investigational Phase 4 923950-08-7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
Metformin Approved Phase 4 657-24-9 4091 14219
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
Insulin glargine Approved Phase 4 160337-95-1
Saxagliptin Approved Phase 4 361442-04-8 11243969
Ribavirin Approved Phase 4 36791-04-5 37542
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Choline Approved, Nutraceutical Phase 4 62-49-7 305
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Metadoxine Experimental Phase 4 74536-44-0

Interventional clinical trials:

(show top 50) (show all 1064)
# Name Status NCT ID Phase Drugs
1 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
2 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
3 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
6 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
7 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
8 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
9 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
10 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
11 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
14 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
15 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
16 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
17 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
18 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
19 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
20 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
21 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
22 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
23 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
24 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
25 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
26 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
27 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
28 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
29 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
30 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
31 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
32 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
33 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease:an Multicenter,Randomized, Double-blind, Parallel- Controlled Study. Completed NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
34 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Completed NCT03849729 Phase 4 Phentermine
35 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
36 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
37 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
38 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
39 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
40 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
41 A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus. Completed NCT03007329 Phase 4 Exenatide;Exenatide matching Placebo;Dapagliflozin
42 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
43 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
44 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
45 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
46 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
47 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
48 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
49 S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease Recruiting NCT04718051 Phase 4 Shen Pu Yang Gan Wan;Placebo
50 The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial - Recruiting NCT04465032 Phase 4

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Genetic Tests for Fatty Liver Disease

Anatomical Context for Fatty Liver Disease

MalaCards organs/tissues related to Fatty Liver Disease:

Liver, Endothelial, Ovary, Skeletal Muscle, Adipocyte, Pancreas, Spleen

Publications for Fatty Liver Disease

Articles related to Fatty Liver Disease:

(show top 50) (show all 30227)
# Title Authors PMID Year
Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. 61 42
33725855 2021
The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. 42 61
33761646 2021
Gender-specific association between non-alcoholic fatty liver disease and type 2 diabetes mellitus among a middle-aged and elderly Chinese population: An observational study. 61 42
33578624 2021
An Expanded Multi-Organ Disease Phenotype Associated with Mutations in YARS. 6
29232904 2017
Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. 61 54
20413174 2010
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 61 54
20363656 2010
Role of cannabinoids in the development of fatty liver (steatosis). 54 61
20204561 2010
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. 61 54
20388526 2010
Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. 54 61
20336705 2010
Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. 54 61
20167877 2010
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 54 61
20415685 2010
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. 61 54
20503453 2010
Longitudinal increase in gamma-glutamyltransferase within the reference interval predicts metabolic syndrome in middle-aged Korean men. 54 61
19922966 2010
Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. 61 54
20142825 2010
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. 54 61
20225248 2010
Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. 54 61
20490434 2010
Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis. 54 61
20457939 2010
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 54 61
19881359 2010
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? 54 61
20406065 2010
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. 61 54
20200515 2010
Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). 54 61
20185760 2010
Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. 61 54
19770674 2010
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 61 54
19931264 2010
Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis. 54 61
19929925 2010
Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. 54 61
19171337 2010
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 61 54
20150538 2010
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. 54 61
20335584 2010
Serum fatty acid composition and insulin resistance are independently associated with liver fat markers in elderly men. 54 61
20022128 2010
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 61 54
20176643 2010
Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 54 61
19817962 2010
Relationship between body mass index and alanine aminotransferase concentration in non-diabetic Korean adults. 61 54
19904291 2010
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. 54 61
20054868 2010
[Critical roles of PPARgamma in every aspect of the metabolic syndrome]. 61 54
20158085 2010
Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. 61 54
20021625 2010
Environmental and genetic determinants of fatty liver in humans. 54 61
20460907 2010
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. 54 61
20040336 2010
Hepatic steatosis in a school population of overweight and obese adolescents. 61 54
20151095 2010
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 61 54
19940802 2010
The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis. 54 61
19656511 2010
Metabolically healthy but obese individuals: relationship with hepatic enzymes. 61 54
19709695 2010
An active part of Artemisia sacrorum Ledeb. attenuates hepatic lipid accumulation through activating AMP-activated protein kinase in human HepG2 cells. 61 54
20139613 2010
Physiological functions of iso-type short-chain fatty acid and omega 3 polyunsaturated fatty acids containing oil in obese OLETF rats. 54 61
20484835 2010
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 61 54
19769633 2009
[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population]. 61 54
19850541 2009
[Clinical and histological features of non-alcoholic fatty liver disease]. 54 61
19958638 2009
Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. 54 61
20501438 2009
Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. 61 54
19525859 2009
Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. 54 61
19278843 2009
[Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease]. 61 54
19923096 2009
The role of resistin as a regulator of inflammation: Implications for various human pathologies. 54 61
19740705 2009

Variations for Fatty Liver Disease

ClinVar genetic disease variations for Fatty Liver Disease:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PRMT7 NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter) SNV Pathogenic 523434 rs1251713297 GRCh37: 16:68389688-68389688
GRCh38: 16:68355785-68355785
2 PRMT7 NM_019023.5(PRMT7):c.322G>T (p.Glu108Ter) SNV Pathogenic 523435 rs1014959895 GRCh37: 16:68363008-68363008
GRCh38: 16:68329105-68329105
3 YARS1 NM_003680.3:c.806T>C SNV Likely pathogenic 996695 GRCh37: 1:33252555-33252555
GRCh38: 1:32786954-32786954
4 MT-TL1 NC_012920.1:m.3275C>T SNV Uncertain significance 370045 rs1057516057 GRCh37: MT:3275-3275
GRCh38: MT:3275-3275
5 OPA1 NM_001354663.2(OPA1):c.-260_-243del Deletion Uncertain significance 214916 rs863224140 GRCh37: 3:193332587-193332604
GRCh38: 3:193614798-193614815

Expression for Fatty Liver Disease

Search GEO for disease gene expression data for Fatty Liver Disease.

Pathways for Fatty Liver Disease

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
19 10.93 LEPR LEP INS

GO Terms for Fatty Liver Disease

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.95 SREBF1 PNPLA3 MTTP LEP GGT1 CYP2E1
2 fatty acid metabolic process GO:0006631 9.91 PPARA GGT1 CYP2E1 ADIPOR2
3 positive regulation of protein kinase B signaling GO:0051897 9.91 TNF LEP INSR INS
4 cholesterol metabolic process GO:0008203 9.87 SREBF1 LEPR LEP
5 insulin receptor signaling pathway GO:0008286 9.85 SREBF1 INSR INS
6 response to nutrient GO:0007584 9.85 LEP ADIPOR2 ADIPOQ
7 response to nutrient levels GO:0031667 9.85 LEP ADIPOR2 ADIPOQ
8 response to bacterium GO:0009617 9.84 SLC17A5 CYP2E1 ADIPOR2 ADIPOQ
9 regulation of insulin secretion GO:0050796 9.82 TNF SREBF1 LEP
10 positive regulation of cold-induced thermogenesis GO:0120162 9.81 LEPR LEP ADIPOR2 ADIPOQ
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 TNF LEP INSR INS
12 circadian rhythm GO:0007623 9.78 SREBF1 MTTP LEP ADIPOQ
13 positive regulation of cytokine production GO:0001819 9.77 TNF LEP INS
14 positive regulation of protein phosphorylation GO:0001934 9.73 TNF LEPR LEP INSR ADIPOR2 ADIPOQ
15 positive regulation of glycolytic process GO:0045821 9.7 MLXIPL INSR INS
16 negative regulation of glucose import GO:0046325 9.69 TNF LEP
17 energy reserve metabolic process GO:0006112 9.68 LEPR LEP
18 intestinal absorption GO:0050892 9.68 LEP FABP1
19 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.68 PPARA ADIPOQ
20 neuron projection maintenance GO:1990535 9.67 INSR INS
21 glucose metabolic process GO:0006006 9.67 TNF LEP INS ADIPOQ
22 regulation of fatty acid biosynthetic process GO:0042304 9.66 ADIPOR2 ADIPOQ
23 leptin-mediated signaling pathway GO:0033210 9.66 LEPR LEP
24 negative regulation of appetite GO:0032099 9.65 PPARA LEP
25 positive regulation of fatty acid beta-oxidation GO:0032000 9.65 PPARA FABP1
26 sexual reproduction GO:0019953 9.65 LEPR LEP
27 negative regulation of lipid storage GO:0010888 9.64 TNF LEP
28 regulation of fatty acid metabolic process GO:0019217 9.63 SREBF1 PPARA
29 regulation of lipid storage GO:0010883 9.63 SREBF1 PPARA
30 positive regulation of lipid biosynthetic process GO:0046889 9.63 PPARA MLXIPL INS
31 response to ethanol GO:0045471 9.63 SREBF1 PPARA LEP CYP2E1 ADIPOR2 ADIPOQ
32 positive regulation of respiratory burst GO:0060267 9.62 INSR INS
33 response to sucrose GO:0009744 9.62 PNPLA3 ADIPOQ
34 positive regulation of glucose import GO:0046326 9.62 INSR INS ADIPOR2 ADIPOQ
35 negative regulation of gluconeogenesis GO:0045721 9.61 LEPR INS ADIPOQ
36 bone growth GO:0098868 9.59 LEPR LEP
37 regulation of bone remodeling GO:0046850 9.58 LEPR LEP
38 positive regulation of developmental growth GO:0048639 9.58 LEP INSR
39 positive regulation of fatty acid metabolic process GO:0045923 9.57 PPARA ADIPOQ
40 positive regulation of protein complex disassembly GO:0043243 9.56 TNF INSR
41 lipid localization GO:0010876 9.55 SREBF1 PPARA
42 cellular response to insulin stimulus GO:0032869 9.43 SREBF1 PNPLA3 LEP INSR GPT ADIPOQ
43 glucose homeostasis GO:0042593 9.17 MLXIPL LEPR LEP INSR INS ADIPOR2

Sources for Fatty Liver Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....